Korean medication algorithm project for bipolar disorder: Third revision

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 493-506

  Woo, Young Sup ^a   Lee, Jung Goo ^b   Jeong, Jong Hyun ^a   Kim, Moon Doo ^c   Sohn, Inki ^d   Shim, Se Hoon ^e   Jon, Duk In ^f   Seo, Jeong Seok ^g   Shin, Young Chul ^h   Min, Kyung Joon ⁱ   Yoon, Bo Hyun ^j   Bahk, Won Myong ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Inje University   (South Korea)

^c Jeju National University College of Medicine   (South Korea)

^d Keyo Hospital   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Hallym University   (South Korea)

^g Konkuk University School of Medicine   (South Korea)

^h School of Medicine   (South Korea)

ⁱ Chung Ang University College of Medicine   (South Korea)

^j Naju National Hospital   (South Korea)

more..

Author keywords

Expert consensus; Pharmacological treatment; Treatment guideline

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; ESCITALOPRAM; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; METFORMIN; MIRTAZAPINE; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ARTICLE; ASSESSMENT OF HUMANS; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CHILD PSYCHIATRY; CONSENSUS; DEPRESSION; DISEASE SEVERITY; DRUG CHOICE; DRUG PREFERENCE; GERIATRIC PATIENT; HUMAN; HYPOMANIA; KOREAN (PEOPLE); KOREAN MEDICATION ALGORITHM PROJECT FOR BIPOLAR DISORDER; MAINTENANCE CHEMOTHERAPY; MEDICAL EXPERT; MENTAL PATIENT; MONOTHERAPY; PRACTICE GUIDELINE; PSYCHIATRIST; QUESTIONNAIRE;

EID: 84924088130     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S77838     Document Type: Article

References (65)

1. No authors listed. Treatment of bipolar disorder. The Expert Consensus Panel for Bipolar Disorder. J Clin Psychiatry. 1996;57 Suppl 12A:3–88.
2. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med. 2000;Spec No:1–104.
3. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 Suppl):1–50.
4. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.
5. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81–109.
6. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009;10(2):85–116.
7. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry. 2004;5(3):120–135.
8. Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry. 2003;4(1):5–13.
9. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry. 2002;3(3):115–124.
10. Goodwin GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17(2):149–173; discussion 147.
11. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346–388.
12. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44.
13. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255.
14. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006;8(6):721–739.
15. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 2005;7 Suppl 3:5–69.
16. Bahk WM, Shin YC, Jon DI, et al. Korean Medication Algorithm for Bipolar Disorder (I). Korean J Psychopharmacol. 2002;13:205–221.
17. Kim CH, Min KJ, Shin YC, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (I): Global assessment. Korean J Psychopharmacol. 2005;16:225–233.
18. Shin YC, Bahk WM, Kim CH, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (II): Choice of medications. Korean J Psychopharmacol. 2005;16:285–291.
19. Jon DI, Bahk WM, Shin YC, et al. Feasibility of Korean Medication Algorithm for Bipolar Disorder (III): Treatment response and tolerability. Korean J Psychopharmacol. 2005;16:292–300.
20. Jon DI, Bahk WM, Yoon BH, et al. Revised Korean medication algorithm for bipolar disorder. World J Biol Psychiatry. 2009;10(4 Pt 3): 846–855.
21. Shin YC, Min KJ, Yoon BH, et al. Korean medication algorithm for bipolar disorder: second revision. Asia Pac Psychiatry. 2013;5(4):301–308.
22. Seok Seo J, Rim Song H, Bin Lee H, et al. The Korean Medication Algorithm for Depressive Disorder: second revision. J Affect Disord. 2014;167:312–321.
23. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs monotherapy. Acta Psychiatr Scand. 2007;115(1):12–20.
24. Lee SM, Shim IH, Woo YS, Jun TY, Bahk WM. [A trend of medication prescription pattern for outpatients with bipolar disorder in a university hospital: focusing on atypical antipsychotics]. Korean J Psychopharmacol. 2014;25(3):124–133. Korean.
25. Cha JM, Shim IH, Woo YS, Jun TY, Bahk WM. A trend of drug use in inpatients with bipolar disorder: comparing 2009–2012 with 1998–2001 in one university hospital. Korean J Psychopharmacol. 2014;25(3):114–123.
26. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079–1088.
27. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351–1360.
28. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26(6):600–609.
29. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71(2):163–174.
30. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13(1):5–14.
31. Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry. 2014;47(2):43–52.
32. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. J Affect Disord. 2011;133(3):361–370.
33. Vieta E, Valenti M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515–529.
34. McIntyre RS, Cha DS, Kim RD, Mansur RB. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18 Suppl 1:4–20; quiz 21.
35. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry. 2011;72(8):1063–1071.
36. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26(5):603–617.
37. Quante A, Zeugmann S, Luborzewski A, et al. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol. 2010;25(2):126–132.
38. Mazza M, Squillacioti MR, Pecora RD, Janiri L, Bria P. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial. Expert Opin Pharmacother. 2008;9(18):3145–3149.
39. Dunn RT, Stan VA, Chriki LS, Filkowski MM, Ghaemi SN. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord. 2008;110(1–2):70–74.
40. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4–9.
41. Vieta E, Valenti M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord. 2013;148(1):28–36.
42. Yildiz A, Vieta E, Tohen M, Baldessarini RJ. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Int J Neuropsychopharmacol. 2011;14(7):863–875.
43. González-Pinto A, Aldama A, Mosquera F, González Gómez C. Epidemiology, diagnosis and management of mixed mania. CNS Drugs. 2007;21(8):611–626.
44. Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013;15(2):115–137.
45. Baldessarini RJ, Hennen J, Wilson M, et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J Clin Psychopharmacol. 2003;23(4):370–376.
46. Vieta E, Calabrese JR, Hennen J, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J Clin Psychiatry. 2004;65(10):1420–1428.
47. Shi L, Schuh LM, Trzepacz PT, Huang LX, Namjoshi MA, Tohen M. Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania. Curr Med Res Opin. 2004;20(9):1371–1376.
48. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1–2):106–115.
49. Suppes T, Eudicone J, McQuade R, Pikalov A III, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008;107(1–3):145–154.
50. Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W; BOLDER Study Group. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9(4):413–425.
51. Muzina DJ, Momah C, Eudicone JM, et al. Aripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled study. Int J Clin Pract. 2008;62(5):679–687.
52. Woo YS, Bahk WM, Pae CU, et al. Observational study to evaluate the clinical benefit of lamotrigine add-on therapy in bipolar patients in a naturalistic treatment setting. Asia Pac Psychiatry. 2014;6(3):334 341.
53. Woo YS, Bahk WM, Jon DI, et al. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(7):1147–1152.
54. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: A review. Clin Ther. 2010;32 Suppl 1:S32–S38.
55. Kemp DE, Karayal ON, Calabrese JR, et al. Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles. Eur Neuropsychopharmacol. 2012;22(2):123–131.
56. Sachs GS, Ice KS, Chappell PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1413–1422.
57. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs. 2007;21(10):835–849.
58. Weisler R, Warrington L, Dunn J. Adjunctive ziprasidone in bipolar mania: Short- and long-term data. Biol Psychiatry. 2004;55:43s–43s.
59. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):213–235.
60. McClellan J, Kowatch R, Findling RL; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107–125.
61. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441–1451.
62. Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11(7):687–700.
63. Pathak S, Findling RL, Earley WR, Acevedo LD, Stankowski J, Delbello MP. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(1):e100–e109.
64. Miller L, Barnett S. Mood lability and bipolar disorder in children and adolescents. Int Rev Psychiatry. 2008;20(2):171–176.
65. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–1529.